[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488761":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":52,"collaborators":20,"id":55,"slug":20,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":20,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with vertebral atherosclerotic stenosis requiring stent implantation","EXPERIMENTAL","Referring to \"the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease\", \"the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus\" and \"Subclavian\u002Fextracranial vertebral artery stenosis: Chinese expert consensus\" in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients.",[13],"Device: The drug-eluting stent",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","The drug-eluting stent","Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Zhong Ji, PHD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","020-62787664","jizhong22@hotmail.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":20},"Kaibin Huang","15915751065",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Nanfang Hospital of Southern Medical University","RECRUITING","Guangzhou","Guangdong","510515","China",{"type":42,"coordinates":43},"Point",[44,45],113.25,23.11667,{"lat":45,"lon":44},[48,49],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":50,"role":27,"phone":32,"phoneExt":20,"email":51},"Kaibing Huang","hkb@smu.edu.cn",{"type":24,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"jizhong","Associate chief physician","100488761",false,"NCT05644314","Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis","Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender is not limited;\n2. Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;\n3. Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;\n2. With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;\n3. Gastrointestinal disease with active bleeding;\n4. Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;\n5. Known contraindications to heparin, rapamycin, anesthesia, and contrast agents;\n6. Life expectancy less than 12 months;\n7. the investigator judged patients to be unsuitable for participation in this study.","ALL","18 Years",{"count":64,"type":65},144,"ESTIMATED","INTERVENTIONAL",[68],"NA","This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.",[71,72],"Ischemic Stroke","Vertebral Artery Stenosis","2023-03-13",{"date":75,"type":76},"2023-03-14","ACTUAL",{"date":78,"type":76},"2022-05-01",{"date":80,"type":65},"2029-05-31",{"name":5,"class":6},1]